Merck & Co. Inc. (MRK) reported third-quarter financial results and lowered the high end of previously issued full-year adjusted-EPS guidance. The company’s vaccine business, propelled by Gardasil, and other products such as Januvia for diabetes have been the catalysts for revenue growth. Mega-blockbuster Singulair as well as Gardasil have recently ...